The Oncology Institute, Inc. TOI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Other Operating Income by Business | ||||||
| Clinical trials & other | $813K+5.3% | $772K+62.9% | $474K-61.1% | $1.22M-31.3% | $1.77M-11.0% | |
| Patient services | $4.25M-26.2% | $5.76M+38.2% | $4.17M+28.0% | $3.26M-27.9% | $4.52M+92.6% | |
| Specialty pharmacy | $16.8M— | —— | —— | —— | $9.4M+31.6% | |
| Total segment amortization by Business | ||||||
| Clinical trials & other | $0— | $0— | $0-100% | $55K0.0% | $55K-50.0% | |
| Patient services | $718K+0.1% | $717K0.0% | $717K-0.1% | $718K0.0% | $718K-50.0% | |
| Total Assets by Business | ||||||
| Clinical trials & other | $6.04M+11.1% | $5.44M+35.1% | $4.03M-15.7% | $4.78M-40.3% | $8M+0.3% | |
| Patient services | $83.12M+11.3% | $74.66M+0.8% | $74.09M+5.8% | $70.03M+6.5% | $65.75M-3.9% | |
| Specialty pharmacy | $29.14M+74.7% | $16.68M— | —— | —— | —— | |
| Depreciation expense by Business | ||||||
| Clinical trials & other | $0-100% | $8K— | $0— | $0-100% | $2K0.0% | |
| Patient services | $737K+11.7% | $660K-10.4% | $737K-3.9% | $767K+1.6% | $755K+8.9% | |
| Specialty pharmacy | $3K— | —— | —— | —— | $32K+3.2% | |
| Total operating revenue by Product | ||||||
| Capitated revenue | $26.93M+14.3% | $23.57M+14.6% | $20.57M+9.2% | $18.84M+7.7% | $17.5M-0.1% | |
| Clinical trials & other | $813K+15.3% | $705K+48.7% | $474K-64.6% | $1.34M-34.6% | $2.05M-17.0% | |
| FFS revenue | $32.16M-11.3% | $36.27M-8.5% | $39.62M+6.9% | $37.05M+4.1% | $35.57M+8.7% | |
| Patient services | $59.09M-1.3% | $59.84M-0.6% | $60.2M+7.7% | $55.89M+5.3% | $53.07M+5.7% | |
| Specialty Pharmacy | $87.54M— | —— | —— | —— | $49.29M+9.6% | |
| Total Assets by Product | ||||||
| Capitated accounts receivable | $1.57M-51.1% | $3.21M+10.7% | $2.9M+28.1% | $2.27M-41.7% | $3.88M+5.1% | |
| FFS accounts receivable | $33.64M-4.9% | $35.38M+0.1% | $35.34M+10.8% | $31.9M+11.6% | $28.59M+7.8% | |
| IV drug inventory | $13.55M+67.7% | $8.08M+6.1% | $7.61M+4.4% | $7.29M+11.8% | $6.52M-0.6% | |
| Oral drug accounts receivable | $10M+34.0% | $7.46M-15.7% | $8.85M-21.4% | $11.26M+47.7% | $7.62M+19.7% | |
| Oral drug inventory | $10.75M+22.2% | $8.8M-22.0% | $11.27M+32.6% | $8.5M+46.8% | $5.79M+66.2% | |
| Other assets | $42.77M+50.5% | $28.42M-19.6% | $35.35M+4.7% | $33.75M+12.2% | $30.09M-17.0% | |
| Direct costs by Product | ||||||
| Clinician salaries and benefits | $15.34M— | —— | $14.77M— | —— | $14.07M— | |
| Intravenous (IV) drug costs | $29.77M— | —— | $36.82M— | —— | $31.41M— | |
| Medical supplies and other | $8.28M— | —— | $2.98M— | —— | $1.59M— | |
| Number of lease modifications by Geography | ||||||
| CALIFORNIA | 1— | —— | —— | —— | —— | |
| FLORIDA | 4— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
